Stock Watch: The Mixed History Of Biotech Company Separations
Was Bluebird’s Split Accompanied By Premature Enthusiasm?
Executive Summary
The path of spin-offs from loss-making biotech companies with weak investment propositions seems clouded with examples that often resulted in an appointment with the liquidator.
You may also be interested in...
Bluebird Revises Business Priorities And Secures Upfront Cash From Bristol
The company is deferring investment in a US commercial team and prioritizing R&D activities, but it outlined an accelerated path to approval for LentiGlobin in sickle cell disease.
Stock Watch: Is Johnson & Johnson Edging Away From Pharma?
J&J’s Medtech division outshone pharma while recently launched innovative products contributed minimally: it is to be hoped investors’ reactions to the first set of big pharma Q1 results will not set the tempo for earnings season.
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.